NCT02688712View on ClinicalTrials.gov

ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 24, 2016

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Rectal Adenocarcinoma
Interventions
DRUG

LY2157299

Small molecule inhibitor of transforming growth factor-beta signaling pathway

DRUG

Capecitabine

Antimetabolite chemotherapy

DRUG

Fluorouracil

Antimetabolite chemotherapy

PROCEDURE

Tumor specific mesorectal excision

Tumor specific mesorectal excision

Trial Locations (1)

97213

Providence Cancer Center, Portland

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Providence Health & Services

OTHER